196 related articles for article (PubMed ID: 29547399)
1. Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism.
Ramms B; Gordts PLSM
Curr Opin Lipidol; 2018 Jun; 29(3):171-179. PubMed ID: 29547399
[TBL] [Abstract][Full Text] [Related]
2. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.
Khetarpal SA; Zeng X; Millar JS; Vitali C; Somasundara AVH; Zanoni P; Landro JA; Barucci N; Zavadoski WJ; Sun Z; de Haard H; Toth IV; Peloso GM; Natarajan P; Cuchel M; Lund-Katz S; Phillips MC; Tall AR; Kathiresan S; DaSilva-Jardine P; Yates NA; Rader DJ
Nat Med; 2017 Sep; 23(9):1086-1094. PubMed ID: 28825717
[TBL] [Abstract][Full Text] [Related]
3. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
[TBL] [Abstract][Full Text] [Related]
4. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Taskinen MR; Packard CJ; Borén J
Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
[TBL] [Abstract][Full Text] [Related]
6. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
Schmitz J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
[TBL] [Abstract][Full Text] [Related]
7. ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors.
Kegulian NC; Ramms B; Horton S; Trenchevska O; Nedelkov D; Graham MJ; Lee RG; Esko JD; Yassine HN; Gordts PLSM
Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):2145-2156. PubMed ID: 31390883
[TBL] [Abstract][Full Text] [Related]
8. Targeting ApoC-III to Reduce Coronary Disease Risk.
Khetarpal SA; Qamar A; Millar JS; Rader DJ
Curr Atheroscler Rep; 2016 Sep; 18(9):54. PubMed ID: 27443326
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
10. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
Reeskamp LF; Tromp TR; Stroes ESG
Curr Opin Lipidol; 2020 Jun; 31(3):140-146. PubMed ID: 32324598
[TBL] [Abstract][Full Text] [Related]
11. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Chan DC; Watts GF
Curr Opin Lipidol; 2024 Jun; 35(3):101-109. PubMed ID: 38372218
[TBL] [Abstract][Full Text] [Related]
12. Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice.
Jong MC; Havekes LM
Int J Tissue React; 2000; 22(2-3):59-66. PubMed ID: 10937355
[TBL] [Abstract][Full Text] [Related]
13. Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans.
Pavlic M; Valéro R; Duez H; Xiao C; Szeto L; Patterson BW; Lewis GF
Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1660-5. PubMed ID: 18556566
[TBL] [Abstract][Full Text] [Related]
14. Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype.
Corbin LJ; Hughes DA; Chetwynd AJ; Taylor AE; Southam AD; Jankevics A; Weber RJM; Groom A; Dunn WB; Timpson NJ
Metabolomics; 2020 Jun; 16(6):69. PubMed ID: 32494907
[TBL] [Abstract][Full Text] [Related]
15. Impact of bariatric surgery on apolipoprotein C-III levels and lipoprotein distribution in obese human subjects.
Maraninchi M; Padilla N; Béliard S; Berthet B; Nogueira JP; Dupont-Roussel J; Mancini J; Bégu-Le Corroller A; Dubois N; Grangeot R; Mattei C; Monclar M; Calabrese A; Guérin C; Desmarchelier C; Nicolay A; Xiao C; Borel P; Lewis GF; Valéro R
J Clin Lipidol; 2017; 11(2):495-506.e3. PubMed ID: 28502507
[TBL] [Abstract][Full Text] [Related]
16. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
Rocha NA; East C; Zhang J; McCullough PA
Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
[TBL] [Abstract][Full Text] [Related]
17. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
[TBL] [Abstract][Full Text] [Related]
18. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
Chan DC; Chen MM; Ooi EM; Watts GF
Int J Clin Pract; 2008 May; 62(5):799-809. PubMed ID: 18201179
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production.
Yao Z; Wang Y
Curr Opin Lipidol; 2012 Jun; 23(3):206-212. PubMed ID: 22510806
[TBL] [Abstract][Full Text] [Related]
20. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.
Gordts PL; Nock R; Son NH; Ramms B; Lew I; Gonzales JC; Thacker BE; Basu D; Lee RG; Mullick AE; Graham MJ; Goldberg IJ; Crooke RM; Witztum JL; Esko JD
J Clin Invest; 2016 Aug; 126(8):2855-66. PubMed ID: 27400128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
